Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) issued its earnings results on Tuesday. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.03, FiscalAI reports. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. The business had revenue of $862.68 million for the quarter.

Here are the key takeaways from Amneal Pharmaceuticals’ conference call:

• Strong Q3 performance: Revenue rose 10% to $863 million, adjusted EBITDA increased 30% to $207 million, and adjusted EPS grew 53% to $0.26, prompting Amneal to raise its 2026 revenue, EBITDA, and EPS guidance.
• Affordable medicines revenue increased 19% to $547 million, supported by women’s health transdermal patches, new product launches, and biosimilar orders. The recently launched lanreotide generated approximately $7 million in late-September sales, with management expecting substantially higher revenue in Q4 and targeting 30%–40% market share.
• The completed Kashiv acquisition gives Amneal integrated biosimilar development, manufacturing, and commercialization capabilities. Management expects $400 million–$500 million of financial benefits over time and recently secured $60 million in New Jersey tax credits tied largely to biosimilar-related expansion.
• Specialty products continued to gain momentum, with CREXONT adding approximately 400 prescribers monthly and BREKIYA tracking ahead of expectations. Management expressed confidence that both products could reach the middle to high end of its long-term outlook.
• Operating cash flow guidance was reduced by $25 million at the midpoint to $325 million–$375 million because Amneal is building finished-goods inventory to meet demand and expects some collections to shift into Q1 2027. Net leverage was 3.0 times adjusted EBITDA after the Kashiv acquisition, with year-end leverage expected to rise to 3.6 times.

Amneal Pharmaceuticals Stock Down 1.1%

AMRX opened at $20.21 on Wednesday. Amneal Pharmaceuticals has a twelve month low of $10.92 and a twelve month high of $21.68. The firm’s 50-day simple moving average is $19.22 and its 200-day simple moving average is $15.82. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The firm has a market cap of $6.45 billion, a price-to-earnings ratio of 23.77, a PEG ratio of 2.38 and a beta of 1.24.

Trending Headlines about Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q3 revenue was $863 million, while adjusted EPS of $0.26 beat analyst estimates of $0.23–$0.24 and rose from $0.17 a year earlier. Adjusted EBITDA was $207 million. Amneal Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Amneal’s updated 2026 full-year outlook slightly exceeded expectations, offering a favorable signal about its near-term business prospects. Amneal beats expectations in Q3, outlook slightly exceeds expectations
• Negative Sentiment: The quarter included a $22 million GAAP net loss and diluted loss per share of $0.06, despite the adjusted profit. Amneal also announced asset impairment charges; the cited report does not specify their amount. These items may have weighed on sentiment alongside the otherwise strong results. Amneal announces asset impairment charges

Insiders Place Their Bets

In related news, Director John Kiely sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the sale, the director owned 210,252 shares of the company’s stock, valued at $3,708,845.28. This trade represents a 19.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

AMRX has been the subject of a number of research analyst reports. Piper Sandler restated an “overweight” rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a report on Wednesday. UBS Group reissued a “buy” rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Oppenheimer initiated coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 target price for the company. Finally, Leerink Partners began coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $23.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $22.62.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.